A phase 3 trial found that adding polatuzumab vedotin to standard chemotherapy (R-GemOx) slashed the risk of death by 40% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who can't receive a stem cell transplant. The Pola-R-GemOx combo also more than doubled complete response rates and extended median overall survival from 12.5 to 19.5 months — a meaningful win for a population with few good options.
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who aren't eligible for a stem cell transplant, treatment options have long been limited — and CAR T-cell therapy, while promising, reaches only a fraction of those who qualify. A new phase 3 trial called POLARGO offers a compelling alternative.
The multicenter trial enrolled 255 patients across 16 countries, randomly assigning them to receive either polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) or the standard R-GemOx regimen alone. Results published in the Journal of Clinical Oncology showed that the Pola-R-GemOx group fared significantly better on every major outcome measured.
By the Numbers:
Why it matters: Only about 25–36% of eligible DLBCL patients actually receive CAR T-cell therapy in real-world settings, leaving a large gap in care. Pola-R-GemOx offers a meaningful, accessible option for transplant-ineligible patients — though its role in those previously treated with polatuzumab-based first-line regimens remains an open question.
